Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
Wolfgang Miesbach/LinkedIn
Oct 16, 2026, 12:49

Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A

Wolfgang Miesbach, Head of Hemostasis/Hemophilia Center at Medical Clinic 2 at University Hospital Frankfurt, shared a post on LinkedIn:

“Five years of real-world emicizumab data, and a question that goes well beyond emicizumab.

Long-term data from the Canadian Bleeding Disorders Registry: 710 people with haemophilia A, followed for up to five years:

  • Mean ABR fell from 1.00 to 0.47
  • 61.8% had no recorded bleed
  • Two thrombotic events, no TMA, no new safety signal
  • These results are reassuring and consistent with HAVEN.

But the baseline matters: most patients started from an ABR of 1.0 on FVIII prophylaxis.

As Cedric Hermans argues in the accompanying commentary, ABR is approaching its floor.

Halving a rate that is already close to zero tells us less and less about how one effective therapy differs from another.

Congratulations to the CBDR team and Alfonso Iorio.”

Title: Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry

Authors: Alfonso Iorio, Federico Germini, Quazi Ibrahim, Arun Keepanasseril, Davide Matino, Emma Iserman, Adrienne Lee, Letizia Polito, Katya Moreno,
Michelle Santos, Man-Chiu Poon

Wolfgang Miesbach

Other posts featuring Wolfgang Miesbach on Hemostasis Today.

Adrienne Lee Alfonso Iorio Arun Keepanasseril Davide Matino Emicizumab Emma Iserman Federico Germini Health Hematology Hemostasis Hemostasis News Hemostasis Today Katya Moreno Letizia Polito Man-Chiu Poon Medicine Michelle Santos Quazi Ibrahim Wolfgang Miesbach
NewsFeed